Skip to search formSkip to main contentSkip to account menu

Tepotinib

Known as: Benzonitrile, 3-(1,6-Dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo-3-pyridazinyl)- 
An inhibitor of MET tyrosine kinase with potential antineoplastic activity. Tepotinib selectively binds to MET tyrosine kinase and disrupts MET… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Tepotinib efficacy in an NSCLC patient with brain metastasis harboring an HLA-DRB1-MET gene fusion.
Alterations in c-MET, a tyrosine kinase receptor encoded by the MET gene, have been reported in in approximately 3% of NSCLC and… 
2020
2020
Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping.
9556Background: Preliminary tepotinib data showed durable activity in pts with NSCLC with METex14 skipping prospectively… 
2020
2020
Lung cancer at ASCO20 Virtual
Immunecheckpoint inhibition (ICI) is an approved treatment approach for both unresectable and completely resected advancedstage… 
2019
2019
Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
Radiotherapy (RT) along with surgery is the mainstay of treatment in head and neck squamous cell carcinoma (HNSCC… 
2018
2018
Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial.
9016Background: MET mutations causing exon 14 skipping (METΔex14) produce c-Met receptors lacking a negative regulatory site… 
2018
2018
Abstract A097: Phase II trial of the c-Met inhibitor tepotinib in patients with advanced non-small cell lung cancer harboringMETexon 14-skipping mutations
Background: Approximately 3-4% of non-small cell lung cancers (NSCLCs) harbor activating mutations of the MET proto-oncogene that… 
2018
2018
Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors
The development of molecularly targeted agents has benefited from use of pharmacodynamic markers to identify “biologically… 
2017
2017
Phase Ib trial of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC): Final data including long-term outcomes.
4087Background: The incidence of hepatocellular carcinoma (HCC), a leading cause of cancer death, is increasing with the… 
2016
2016
Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.
e20501Background: Patients (pts) with NSCLC treated with EGFR inhibitors (EGFRi) ultimately develop resistance, often through c… 
2016
2016
Tolerability and activity of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC).
4072Background: Patients (pts) with advanced HCC have a poor prognosis, particularly if tumor c-Met activity is aberrant. Current… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)